^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    YAP1 (Yes associated protein 1)

    i
    Other names: YAP2, YAP, Yes-Associated Protein 2, Yorkie Homolog, COB1, Protein Yorkie Homolog, YAP65, Yes-Associated Protein 1, Transcriptional Coactivator YAP1, YAP1, Yes associated protein 1, Yes-Associated Protein YAP65 Homolog
    3d
    Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy. (PubMed, EMBO Mol Med)
    Finally, we develop a highly accurate predictive model (AUC ≥ 0.90) by the signatures of mitochondrial complex I-mediated anti-tumor immune response and validate it in independent cohorts. This study provides a rich resource for investigating the mechanisms and indicators of immunotherapy in ESCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • YAP1 (Yes associated protein 1)
    5d
    Do drugs with biliary toxicity cause cholangiocarcinoma? (PubMed, bioRxiv)
    Furthermore, we analyzed the CCA incidence in our healthcare system and determined it to be 0.0932% (Augmentin group) and 0.0799% (amoxicillin control group). Similarly, we found no evidence for cholangiocarcinoma development with other commonly used drugs, including chlorpromazine, floxuridine, 5-fluorouracil, flucloxacillin and terbinafine. We conclude that there is no direct causal relationship between clinical Augmentin doses and CCA development.
    Journal
    |
    YAP1 (Yes associated protein 1)
    |
    5-fluorouracil • chlorpromazine
    6d
    Role of Surrogate Immunohistochemistry Markers in CNS Tumors in the Era of Molecular Diagnostics With Recent Updates. (PubMed, Adv Anat Pathol)
    The review emphasizes that when interpreted alongside histomorphology and conventional markers, surrogate immunohistochemistry can significantly reduce reliance on molecular testing, expedite diagnosis, and improve accessibility of precision diagnostics. Standardization, validation, and awareness of pitfalls remain essential to maximizing their clinical utility in neuropathology practice.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ATRX (ATRX Chromatin Remodeler) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • BCOR (BCL6 Corepressor) • YAP1 (Yes associated protein 1) • VIM (Vimentin) • STAT6 (Signal transducer and activator of transcription 6) • L1CAM (L1 cell adhesion molecule) • DUX4 (Double Homeobox 4) • FOXR2 (Forkhead Box R2) • GAB1 (GRB2 Associated Binding Protein 1)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • IDH mutation + BRAF V600E
    7d
    Targeting eIF4A-dependent translation in genetically complex sarcoma. (PubMed, JCI Insight)
    The eIF4A inhibitor CR-1-31B effectively suppressed tumor growth and induced apoptosis in DDLS, MFS, and UPS patient-derived cell lines and mouse xenografts...Genomic analysis of patient tumors revealed that YAP and WWTR1 were frequently amplified or gained in DDLS, MFS, and UPS and were associated with worse clinical outcomes. Together, our findings identify a new strategy for targeting the Hippo pathway in incurable forms of sarcoma based on inhibition of eIF4A-dependent translation of the key oncogenic transcription factors YAP and TAZ.
    Journal
    |
    YAP1 (Yes associated protein 1) • WWTR1 (WW Domain Containing Transcription Regulator 1)
    |
    CR-1-31-B
    7d
    TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma. (PubMed, Oncogene)
    Our results also demonstrate that inducible knockdown of TAK1 in human RMS xenografts retards tumor growth and enhances myogenic differentiation in vivo. Collectively, these findings uncover a previously unrecognized role for TAK1 in RMS growth and differentiation, and suggest that TAK1 can be a potential therapeutic target for the treatment of RMS.
    Journal
    |
    YAP1 (Yes associated protein 1)
    10d
    Retinoblastoma Proficient Small Cell Carcinoma: A Novel Entity with Therapeutic Vulnerability? (PubMed, J Thorac Oncol)
    More importantly, RB1 functional status may also modulate sensitivity to additional therapeutic modalities, highlighting its broader relevance to the evolving SCLC treatment landscape. Integrating molecularly informed strategies accounting for RB1 proficiency and its transcriptional landscape will be pivotal to overcoming the long-standing therapeutic impasse in SCLC, offering a roadmap for the development of effective, precision-guided therapies.
    Review • Journal • IO biomarker
    |
    RB1 (RB Transcriptional Corepressor 1) • YAP1 (Yes associated protein 1)
    11d
    PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer. (PubMed, Cell Death Dis)
    This liberates YAP1 to translocate into the nucleus and initiate a pro-EMT gene expression program. Finally, we demonstrate that the drug candidate SN-38 suppresses metastasis by interfering with this PMEPA1/YAP1 signaling module.
    Journal
    |
    YAP1 (Yes associated protein 1) • ITK (IL2 Inducible T Cell Kinase) • LATS1 (Large Tumor Suppressor Kinase 1)
    12d
    Ferroptosis as a Translational Axis in Small Cell Lung Cancer: A Systematic Review of Redox Pathways and Precision Oncology Prospects. (PubMed, Oncol Res)
    Ferroptosis constitutes a promising therapeutic axis in SCLC. Integrating ferroptosis biomarkers into molecular stratification frameworks could refine patient selection and support precision oncology strategies, warranting further translational and clinical validation.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • YAP1 (Yes associated protein 1) • STING (stimulator of interferon response cGAMP interactor 1) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • POU2F3 (POU Class 2 Homeobox 3) • SLC7A11 (Solute Carrier Family 7 Member 11) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
    12d
    Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant lines. (PubMed, bioRxiv)
    Importantly, co-targeting these pathways was able to overcome resistance to TEADi and was superior to MEK/mTOR/FAK inhibition alone. These studies provide a compelling proof-of-concept that TEADi represents a novel therapeutic vulnerability in meningioma and reveal adaptive signaling responses that can be therapeutically exploited.
    Journal
    |
    NF2 (Neurofibromin 2) • YAP1 (Yes associated protein 1)
    12d
    Co-repression of Yap1 and Sox9 Abrogates Established Cholangiocarcinoma by Eliminating Transcriptional Compensation. (PubMed, Clin Mol Hepatol)
    Co-targeting SOX9 and YAP1 offers a promising and safe broad-spectrum preventive/therapeutic approach for iCCA, potentially overcoming resistance to YAP1 inhibition. The adaptive resistance mechanism identified may extend to other malignancies, providing insights for addressing the advanced resistant to YAP1-TEAD-directed therapies.
    Journal
    |
    YAP1 (Yes associated protein 1) • SOX9 (SRY-Box Transcription Factor 9) • MGAT5 (Alpha-1,6-Mannosylglycoprotein 6-Beta-N-Acetylglucosaminyltransferase)